As of 2026-03-15, the Relative Valuation of Blueprint Medicines Corp (BPMC) is (43.95) USD. This relative valuation is based on P/E multiples. With the latest stock price at 129.46 USD, the upside of Blueprint Medicines Corp based on Relative Valuation is -133.9%.
The range of the Relative Valuation is (41.95) - (47.78) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 17.4x - 19.8x | 18.2x |
| Forward P/E multiples | 17.3x - 19.9x | 18.2x |
| Fair Price | (41.95) - (47.78) | (43.95) |
| Upside | -132.4% - -136.9% | -133.9% |
| Date | P/E |